A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

Mati Therapeutics Inc.15 enrolled

Overview

The objective of this study is to investigate how the intraocular pressure (IOP)-lowering effect of the L-PPDS is altered by adjunctive Xalatan therapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Ocular Hypertension Open-Angle Glaucoma

Interventions

Latanoprost Punctal Plug Delivery SystemDRUG

To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.

XalatanDRUG

Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Over 18 years * Diagnosed with bilateral Open-Angle Glaucoma or Ocular Hypertension * Currently on prostaglandin therapy Exclusion Criteria: * Uncontrolled medical conditions * Subjects who wear contact lenses * Subjects requiring chronic topical artificial tears, lubricants, and /or - requiring any other chronic topical medications

Locations (1)

Menlo Park

Menlo Park, California, United States

Outcomes

Primary Outcomes

Change from baseline in IOP measurements

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.